Lab work is "high mix, low volume," like driving, making it hard to automate. Traditional automation is like a subway: efficient but inflexible. AI enables "autonomous" labs, akin to Waymo cars, that handle the vast variability of experiments, which constitutes 99% of lab work.

Shaking a microtiter plate below a certain "critical shaking speed" is ineffective and equivalent to no mixing at all. A minimum centrifugal force is needed to break the liquid's surface tension. This threshold depends on fill volume, media, and shaking diameter, and must be exceeded for effective screening.

The most common failure in automation is focusing on the robot or software. True success is determined by deeply understanding and codifying the entire process, including its environment and inherent variabilities. Getting the requirements right is the core challenge; the technology itself is secondary.

A key benefit of autonomous labs isn't just speed but perfect documentation. AI-driven systems eliminate human variability—like slight changes in pipetting angle—that is impossible to document but critical for reproducibility. This creates the pristine, detailed data needed for advanced AI models to learn effectively.

The biotech industry often believes its processes require unique, specialized robots. In reality, well-proven robotics from industrial and logistics sectors are applicable. The key is thoughtful system design and adaptation (e.g., sterilization, end effectors), not reinventing core technology.

Beyond clinical validation, the adoption of novel biomarkers like microRNA is hindered by practical lab issues. Disagreements over sample type (serum vs. plasma), establishing universal cutoffs, and achieving high concordance between different testing centers are critical, non-clinical hurdles that must be overcome for widespread clinical use.

To ensure patients get the same result from any test provider, the field must standardize not just the underlying sequencing technology, but also the software pipelines for data analysis and the clinical frameworks for interpreting results. Each layer presents a unique harmonization challenge.

Despite labs being human-centric, humanoid robots are a poor solution. The primary task is moving samples, which specialized tracks do better. Biology, like chip manufacturing, is a microscopic discipline where the goal is to remove human-scale limitations, not replicate them with robots.

Scientists won't adopt automation if they have to code or use clunky visual programmers. The breakthrough is using AI models to translate natural language protocols into robot commands. This removes the primary usability barrier and prevents common user errors, enabling adoption.